GeoVax Labs, Inc., a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, has executed a Master Services Agreement (MSA) with Advanced Bioscience Laboratories, Inc. (ABL) to support current Good Manufacturing Practices (cGMP) production of the company’s vaccine candidates, including GEO-MVA and GEO-CM04S1.
GeoVax Labs and decentralised trial global organisation EmVenio Research have announced a partnership for the deployment of a mobile clinical facility in the US for a Phase II Covid-19 booster vaccine study.
GeoVax Labs, Inc., a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced its clinical trial of Gedeptin for patients with recurrent head and neck cancers is now actively enrolling patients at three major research centres -- Stanford University, Emory University and Thomas Jefferson University.
GeoVax Labs, a biotechnology company focused on the development of vaccines and immunotherapies, announced on April 26, 2022 that the US Patent and Trademark Office has issued a patent that covers the company’s modified vaccinia Ankara (MVA) vector expressing certain antigens from the malaria parasite.
GeoVax Labs has engaged CATO SMS as the company’s clinical research organisation (CRO) partner to manage two Phase II clinical trials of its Covid-19 vaccine candidate, GEO-CM04S1.
LOS ANGELES & ATLANTA--(BUSINESS WIRE)--A COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to GeoVax Labs Inc. (Nasdaq: GOVX), produced a robust neutralizing antibody and T cell (an immune cell) response against SARS-CoV-2 with no significant side effects in a Phase 1 clinical trial led by John Zaia, M.D., Aaron D. Miller and Edith Miller Chair for Gene Therapy, according to a study published in The Lancet Microbe.
GeoVax Labs has commenced subject dosing in the Phase II segment of nits Phase I/II clinical trial to analyse the potential of experimental nCovid-19 vaccine, COH04S1, as a universal booster.
Shares in GeoVax Labs were up as much as 36% Friday after the company presented data from ongoing studies of its preventive vaccine against COVID-19 at the European Society of Medicine (ESMED) general assembly, as reported in Fidelity.
ATLANTA, GA, October 26, 2020 – GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the signing of a Patent and Biological Materials License Agreement (the “License Agreement”) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), in support of GeoVax’s development of a vaccine against SARS-CoV-2, the virus that causes COVID-19. The Patent License Agreement to GeoVax includes access to NIAID’s patent rights in the stabilized SPIKE protein, which is the protein that SARS-CoV-2 uses to gain entry into human tissue.
GeoVax Labs (NASDAQ:GOVX) has closed its public offering of 2.56M units, pre-funded warrants and warrants yielding gross proceeds of $12.8M.